A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)

• Status: Terminated
• Trial end date: 2008-08-26
• Target enrollment: 0
• Participant gender: All

Summary

A 12-Week Efficacy Study in participants with Peripheral Arterial Disease. the primary hypothesis is that MK-0736 7 mg administered once daily for 12 weeks will result in a decrease in lower extremity atherosclerotic plaque macrophage content when compared to placebo (an approximate decrease of up to 30% is expected).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Collaborator: FoxHollow Technologies

Criteria

Inclusion Criteria:

• Participants with peripheral arterial disease

• Participants must be 18 to 85 years of age

• Females must be postmenopausal or sterile

Exclusion Criteria:

• Participans with hepatic, HIV, endocrine, connective tissue, psychiatric disorders or uncontrolled hypertension